Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00ERV
|
|||
| Former ID |
DNC000672
|
|||
| Drug Name |
Gallopamil
|
|||
| Synonyms |
16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2 | [1] | |
| Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Discontinued in Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H40N2O5
|
|||
| Canonical SMILES |
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC
|
|||
| InChI |
1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
|
|||
| InChIKey |
XQLWNAFCTODIRK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 16662-47-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
854012, 5588061, 7979354, 8151048, 10510120, 11120269, 11120757, 11121245, 11121448, 11121928, 11362517, 11365079, 11367641, 11370305, 11370306, 11373242, 11375803, 14834960, 24439579, 26752312, 26752313, 47440013, 47810532, 47885193, 47885194, 48110231, 48258991, 49878993, 50105237, 50105238, 57320831, 76626821, 85087629, 85286057, 85787221, 85788738, 90341545, 91721411, 92309799, 96024702, 99300713, 103235960, 103845994, 103925610, 104171189, 104297146, 117513596, 124749992, 124880746, 124880747
|
|||
| ChEBI ID |
CHEBI:34772
|
|||
| SuperDrug ATC ID |
C08DA02
|
|||
| SuperDrug CAS ID |
cas=016662478
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00896428) Effects of Gallopamil in Severe Asthma (REMODEL'ASTHME) in University Hospital, Bordeaux. | |||
| REF 2 | Mechanism of Vasopeptidase Inhibitor-Induced Plasma Extravasation: Comparison of Omapatrilat and the Novel Neutral Endopeptidase 24.11/Angiotensin-Converting Enzyme Inhibitor GW796406. JPET December 2005 vol. 315 no. 3 1306-1313. | |||
| REF 3 | Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. | |||
| REF 4 | Interaction of D-600 with the transmembrane domain of the sarcoplasmic reticulum Ca(2+)-ATPase. Am J Physiol Cell Physiol. 2000 Jul;279(1):C166-72. | |||
| REF 5 | Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15. | |||
| REF 6 | Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.